Navigation Links
Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009
Date:5/26/2009

PRINCETON, N.J., May 26 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) is scheduled to host a conference call and live webcast at 4:00 p.m. Eastern Time on Tuesday, June 2, 2009. Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex will provide an update and recent highlights from Medarex's pipeline.

The webcast of the live event and archive can be accessed through the Investor Relations section of Medarex's website at www.medarex.com. To access the call live, please dial 1-877-874-1567 (U.S./Canada) or 1-719-325-4768 (international).

An archived telephonic replay of the conference call will be available until midnight Eastern Time on June 9, 2009. Access numbers for this replay are 1-888-203-1112 (U.S./Canada) or 1-719-457-0820 (international); the replay passcode is 4826956.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently approved for commercial sale, the subject of regulatory applications for marketing authorization, or in Phase 3 clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex Announces 2009 First Quarter Financial Results
2. Medarex to Host Business and Financial Update Conference Call on Thursday, April 30, 2009
3. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
4. Medarex to Present at the Needham Cancer Therapeutics Conference
5. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
6. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
7. Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
8. Medarex to Present at the RBC Capital Markets Healthcare Conference
9. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
10. Medarex Announces 2008 Third Quarter Financial Results
11. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... platform specifically designed for life science researchers to analyze and interpret datasets, ... Franklin, who made a major contribution to the discovery of the double-helix ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back ... 8th June 2018 in San Francisco, CA. The Summit brings together current and former ... CEOs, board directors and government officials from around the world to address key issues ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
Breaking Biology Technology:
(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a medical ... (IV) therapy, today announced receipt of its ISO 13485 Certification, the ... the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early detection ... "This is an important ...
(Date:5/23/2017)... 23, 2017  Hunova, the first robotic gym for the rehabilitation and ... launched in Genoa, Italy . The first 30 robots ... the USA . The technology was developed and patented ... the IIT spin-off Movendo Technology thanks to a 10 million euro investment ... please click: ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
Breaking Biology News(10 mins):